Potential Role of Magrolimab in the Treatment of Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) : Episode 8

The Role of Hypomethylating Agents (HMAs) in Higher-Risk Myelodysplastic Syndrome Treatment

October 20, 2022

By Hetty E. Carraway, MD
Eytan M. Stein, MD

Video

Key opinion leaders describe the role of hypomethylating agents in treating higher-risk MDS and the treatment options after HMA failure.

EP: 1.An Overview of Myelodysplastic Syndrome (MDS)

EP: 2.The Progression of Myelodysplastic Syndrome to Acute Myeloid Leukemia (AML)

EP: 3.Risk Stratification for Patients with Myelodysplastic Syndrome

EP: 4.Treatment Goals for Patients with Myelodysplastic Syndrome

EP: 5.Currently Available Treatment Options for Patients with Higher-Risk Myelodysplastic Syndrome

EP: 6.Factors for Consideration when Choosing an Appropriate Treatment for Higher-Risk Myelodysplastic Syndrome

EP: 7.The Role of Allogeneic Stem Cell Transplant in Myelodysplastic Syndrome

Now Viewing

EP: 8.The Role of Hypomethylating Agents (HMAs) in Higher-Risk Myelodysplastic Syndrome Treatment

EP: 9.Magrolimab plus Azacitidine for Myelodysplastic Syndrome

EP: 10.Potential Shift in the Treatment Paradigm of Higher-Risk MDS with Magrolimab

EP: 11.Treating Patients with Myelodysplastic Syndrome and IDH or TP53 Mutations

EP: 12.Unmet Needs for Patients with Higher-Risk Myelodysplastic Syndrome

EP: 13.ENHANCE-2 Trial of Magrolimab plus Azacitidine in AML

EP: 14.ENHANCE-3 Trial of Magrolimab in Combination with Venetoclax and Azacitidine in AML

Related Content

FDA Approves Revumenib in KMT2A-Rearranged Acute Leukemia

Jordyn Sava

November 15th 2024

Article

Revumenib is now an FDA-approved treatment for adult and pediatric patients with relapsed/refractory KMT2A-rearranged acute leukemia.

Revumenib for NPM1-Mutant AML Succeeds in Pivotal Trial

Jordyn Sava

November 12th 2024

Article

In the phase 2 AUGMENT-101 trial, revumenib met its primary end point by achieving a complete remission or complete remission with partial blood count recovery in relapsed/refractory NPM1-mutant acute myeloid leukemia.

$FDA Greenlights Obe-cel in Relapsed/Refractory B-ALL$

FDA Greenlights Obe-cel in Relapsed/Refractory B-ALL

Jordyn Sava

November 8th 2024

Article

The FDA approved obecabtagene autoleucel for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.

Uproleselan With Chemo Fails to Improve EFS in Older Patients With AML

Jordyn Sava

November 2nd 2024

Article

A phase 2/3 study investigating uproleselan with standard 7+3 chemotherapy in newly diagnosed, older patients with acute myeloid leukemia did not achieve the primary end point of improved event-free survival.

FDA Expands Approval for Jylamvo Oral Methotrexate Solution in ALL

Sabrina Serani

October 29th 2024

Article

The indication for Jylamvo now includes pediatric patients with acute lymphoblastic leukemia.

$FDA Fast Tracks HC-7366 in Relapsed/Refractory Acute Myeloid Leukemia$